GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven …
Full GSK analysis →
Competitive advantage assessment
Key strengths
ROIC Sustainably Above PeersROIC at 84.2th percentile exceeds peers and WACC, demonstrating superior capital allocation.
Operating Leverage in EffectOperating leverage is evident (score 0.67), with margins expanding over time.
Key risks
Liquidity ConcernsLiquidity is concerning (score 0.21), raising questions about short-term obligations.
GSK plc ranks #11 of 20
scored companies in Drug Manufacturers - General by moat score — the top 55%.
The widest moat in the group is Novo Nordisk A/S (NVO)
at 74/100.
Moat scores for companies ranked near GSK in Drug Manufacturers - General
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 33
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 56
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 53
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 42
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 59
· 15% of the moat score
Scale matters only when it converts into economics.
GSK plc (GSK) scores 52 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #11 of 20 scored companies in Drug Manufacturers - General, the top 55%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 19 companies in Drug Manufacturers - General. Its strongest defense is Pricing Power (59/100) and its weakest is Cost Advantage (33/100).
How does GSK plc compare with other Drug Manufacturers - General companies?
GSK plc ranks #11 of 20 scored companies in Drug Manufacturers - General by moat score. The widest moat in Drug Manufacturers - General is Novo Nordisk A/S (NVO) at 74/100. The companies ranked closest are Astrazeneca PLC (AZN) at 52 just above it and Grifols, S.A. (GRFS) at 50 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 19 companies in Drug Manufacturers - General. The defenses are then weighted to produce the overall score out of 100.
Why is GSK plc scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for GSK plc?
The Corporate Default template measures 6 defenses, and GSK scores: Pricing Power (59), Cost Advantage (33), Customer Stickiness (56), Capital Efficiency (53), Resilience (42), Scale & Market Position (59). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.